How Does the New Triple-Action Drug Retatrutide Halt Obesity-Related Cancer Progression?
Reading tools
In this article
A new preclinical study in mouse models showed that the triple incretin agonist retatrutide (LY3437943) reduced tumor volume compared with controls by approximately 14-foldin obesity-related pancreatic cancer and approximately 17-fold in lung cancer. The findings were published on 14 March 2025 in npj Metabolic Health and Disease .1
Obesity is a serious public health problem that is becoming increasingly common worldwide and raises the risk of at least 13 different cancers. As next-generation GLP-1/GIP-based weight-loss drugs rapidly gain ground, an important question has emerged in oncology: could these powerful drugs do more than reduce weight and also slow obesity-related cancer development and progression? This is among the first studies to investigate, preclinically, the direct effects on cancer biology of retatrutide, which targets three different hormone receptors simultaneously.
Why Does This Study Matter?
The obesity–cancer relationship and the current treatment gap
- Scale: More than 40% of US adults have obesity (NHANES data); worldwide, according to World Health Organization data for 2022, approximately 16% of adults have obesity and 43% are overweight or obese. Thus, the “40%” figure is a US-specific statistic, not a global one.
- Cancer risk: Obesity increases the risk of at least 13 different cancers, including breast (postmenopausal), colorectal, pancreatic, liver, kidney, uterine (endometrial), and esophageal cancer. In cancer patients, it is also associated with metastasis, poor treatment response, higher recurrence risk, and increased risk of death.
- Treatment gap: Lifestyle interventions often fall short because of poor adherence; bariatric surgery is effective but is not suitable for every patient.
- Next-generation drugs: Incretin-based drugs such as semaglutide (GLP-1) and tirzepatide (GIP/GLP-1) have revolutionized obesity treatment; retatrutide takes this a step further as a triple-action molecule simultaneously targeting GLP-1, GIP, and glucagon receptors.
Study overview
- Drug: Retatrutide (LY3437943)—a triple incretin agonist simultaneously stimulating GLP-1, GIP, and glucagon receptors.
- Model: Diet-induced obese (DIO) mice; the KPCY cell line was used for pancreatic cancer and the Lewis lung carcinoma (LLC) cell line for lung cancer.
- Comparison arms: Control (vehicle), semaglutide, weight matching through calorie restriction (WM-CR), and retatrutide.
- Journal: npj Metabolic Health and Disease, volume 3, article 10, 14 March 2025 (open access).
- Stage: Entirely preclinical (animal model)—no human data yet.
In the Pancreatic Cancer Model: Retatrutide vs Semaglutide
| Arm | Tumor volume (compared with control) | Tumor engraftment |
|---|---|---|
| Control (vehicle) | Reference (1×) | %100 (10/10) |
| Semaglutide (single GLP-1 agonist) | ~4-fold reduction | Not reported separately |
| Retatrutide (triple agonist) | ~14-fold reduction | %70 (7/10) |
Approximate mean tumor volume remaining with retatrutide and semaglutide as a percentage of control—the shorter the bar, the greater the tumor reduction.
Does Protection Disappear Completely After Stopping the Drug?
One notable finding was that some benefits persisted even after retatrutide treatment ended. Although mice regained some weight after discontinuation: protection against tumor engraftment was lost and the rate returned to the control level (100%); however, tumor volume/growth remained significantly suppressed and fasting blood glucose remained approximately 16% lower than in controls. Protection is therefore not fully “permanent”: some effects (tumor growth rate and metabolic improvement) persist despite weight regain, while others (preventing new tumor engraftment) may disappear.
Results in the Lung Cancer Model
Retatrutide's protective effect was not limited to the pancreatic cancer model. Substantial benefits were also observed in the obesity-related Lewis lung carcinoma (LLC) model:
- Tumor engraftment fell by 50% compared with controls (meaning tumors did not establish in half the mice).
- Tumor onset was significantly delayed (a mean of day 16 in the retatrutide group versus day 10 in controls).
- Tumor volume was approximately 17-fold lower than in controls.
Mechanism: How Is the Immune System Reprogrammed?
Two abbreviations to know
- MDSCs (myeloid-derived suppressor cells): Cells that suppress the immune system, helping tumors “hide” from it. As their numbers decrease, the immune system's ability to recognize and attack the tumor increases.
- APCs (antigen-presenting cells): Cells that “show” tumor targets to T cells and trigger an immune response (e.g., macrophages and dendritic cells). This study specifically reported an increase in macrophages with high MHC-II expression.
The researchers reported that sustained antitumor immunity was associated with the following changes both systemically and within the tumor microenvironment:
- Increased circulating IL-6 (interleukin-6)—modest in the pancreatic model but substantial, approximately 4.6-fold, in the lung (LLC) model.
- Decreased monocytic and PMN-type MDSCs.
- Enhanced tumor antigen presentation through increased macrophages with high MHC-II expression (antigen-presenting cells).
- Activation in tumor tissue of pathways associated with antitumor immune responses, such as TNFα-NFκB signaling and interferon-gamma and interferon-alpha responses, with suppression of glycolysis and fatty acid metabolism pathways.
Unlike the chronic, dysfunctional inflammation common in obesity, these changes suggest a more “functional” pattern of immune activation that strengthens antitumor immune surveillance.
Study limitations
- Entirely preclinical: The findings come from mouse models and may not fully reflect human physiology. Only clinical trials can establish whether the effect also occurs in humans.
- Mechanism not clarified: The precise contribution of each GLP-1, GIP, and glucagon receptor pathway to the antitumor effect has not yet been separated.
- Dose and safety: Preclinical doses may not correspond directly to doses used for obesity treatment in humans; human data are needed to establish the safety profile in cancer.
- Weight loss or a direct drug effect? It is difficult to establish how much antitumor benefit comes directly from immune modulation and how much from metabolic improvements due to rapid, substantial weight loss. Although the weight-matched calorie restriction (WM-CR) arm partly addresses this question, it does not fully separate the effects.
Current Status: Is Retatrutide Approved?
Approval status (as of August 2026): Not yet approved by the FDA, EMA, or TİTCK
- Retatrutide is not yet approved by the FDA, EMA, or TİTCK for obesity or diabetes; it remains an investigational molecule.
- The Phase 3 TRIUMPH program reported positive results: TRIUMPH-1 results announced on 21 May 2026 reported weight loss of up to 28.3% at week 80 and 30.3% at week 104 (at the 12 mg dose), versus 2.2% with placebo. TRIUMPH-2 (type 2 diabetes + obesity, ~20.8% weight loss, HbA1c reduction of up to 1.6 points) and TRIUMPH-3 (severe obesity + cardiovascular disease, ~22.6% weight loss), announced on 23 July 2026, also met their goals.
- Next step: Manufacturer Eli Lilly announced plans for an FDA application (BLA) in the first quarter of 2027; no formal application has yet been submitted.
- Situation in Türkiye: Because retatrutide is not approved in any country, it has no TİTCK authorization and is not sold in pharmacies in Türkiye. After approval, its arrival in Türkiye will need to be monitored separately, as with other incretin drugs.
Related Recent Publications (2025)
August 2025 — The Lancet Diabetes & Endocrinology: body composition substudy
In a phase 2 substudy in patients with Type 2 diabetes, retatrutide at the 8 mg dose produced a greater reduction in fat mass (26.1%) at week 36 than placebo (4.5%). Lean (muscle) mass loss as a proportion of total weight lost remained comparable to other obesity drugs, meaning it did not cause disproportionate muscle loss.
May 2025 — Biomolecules: “A Game Changer in Obesity Pharmacotherapy”
A comprehensive review by Katsi and colleagues described retatrutide as a potential “game changer” in obesity treatment, summarizing its effects on weight loss, glycemic control, and fatty liver while raising unanswered questions about cost and the “quality of weight loss.”
An expert perspective: retatrutide and obesity-related cancer
Why does this news matter?
It is among the first strong preclinical signals that next-generation incretin drugs used against obesity may affect cancer biology directly, beyond weight loss. By targeting three receptors simultaneously, retatrutide showed a greater antitumor effect than single GLP-1 agonists (semaglutide).Strengths
Consistent, large effects in two cancer models (pancreatic and lung), with a 14-17-fold reduction in tumor volume; mechanistic evidence suggesting that the effect may involve immune reprogramming (reduced MDSCs, increased antigen presentation, and activation of antitumor signaling pathways), beyond weight loss alone; and partial persistence of some benefits after discontinuation.Limitations
Entirely preclinical (mouse) data—not yet tested in humans; the contribution of each receptor (GLP-1/GIP/glucagon) remains unclear; the extent to which weight loss can be separated from direct drug effects is uncertain; protection against tumor engraftment disappears after discontinuation.What changes in practice?
Nothing for now—retatrutide is not approved and is not prescribed for cancer treatment or prevention. However, the findings reinforce that incretin-based drugs are a research area worth following in oncology as well.Open questions
Will these effects occur in humans, and at what doses will they be safe? Would the antitumor effect be beneficial or neutral in patients undergoing cancer treatment (e.g., alongside immunotherapy)? After retatrutide approval, will dedicated phase 3-4 trials be planned to prevent obesity-related cancers?This article is an objective, evidence-based summary, originally in Turkish, of the preclinical study published in npj Metabolic Health and Diseaseand related recent publications; it is not individual medical advice. Retatrutide is currently neither approved nor commercially available.
References:
- Marathe SJ, Grey EW, Bohm MS, et al. Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression. npj Metabolic Health and Disease. 2025;3:10. nature.com
- Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2 trial. Lancet Diabetes Endocrinol. 2025;13(8):674-684. thelancet.com
- Katsi V, Koutsopoulos G, Fragoulis C, ve ark. Retatrutide—A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15(6):796. mdpi.com
- Eli Lilly. TRIUMPH-1 faz 3 sonuçları basın açıklaması, 21 Mayıs 2026. investor.lilly.com
- Eli Lilly. TRIUMPH-2 ve TRIUMPH-3 faz 3 sonuçları basın açıklaması, 23 Temmuz 2026. investor.lilly.com
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.